The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • AFT Pharmaceuticals (AFP) has opened its NZ$2 million (A$1.88 million) share purchase plan
  • This share purchase plan forms part of the company’s capital raising that was announced on June 10, with the company also announcing a NZ$10 million (A$9.42 million) placement
  • Eligible shareholders will be able to purchase up to NZ$50,000 (A$47,000) worth of new shares at NZ$3.75 (A$3.54) each
  • Shares will be allocated on July 2 and then begin trading on the NZX on July 2 and the ASX on July 3
  • AFT will use the money from both the placement and share purchase plan to increase liquidity and reduce debt
  • AFT has ended the day a slight 2.21 per cent in the green with shares trading for $3.70 each

AFT Pharmaceuticals (AFP) has opened its NZ$2 million (A$1.88 million) share purchase plan.

This share purchase plan forms part of the company’s capital raising that was announced on June 10, with the company also announcing a NZ$10 million (A$9.42 million) placement.

A day later the placement was completed with 2.7 million shares issued at a price of NZ$3.75 (A$3.54) each.

This price was a 20.2 per cent discount to the close on June 9 of NZ$4.70 (A$4.43) per share and an 11.1 per cent discount to the 30-day volume-weighted average price of NZ$4.22 (A$3.98).

For the share purchase plan eligible shareholders will be able to purchase up to NZ$50,000 (A$47,000) worth of new shares at the same price as the placement.

The plan is expected to close on June 26 and share will be allocated on July 2. The shares will then begin trading on the NZX on July 2 and the ASX on July 3.

AFT will use the money from both the placement and share purchase plan to increase liquidity and reduce debt.

AFT has ended the day a slight 2.21 per cent in the green with shares trading for $3.70 each in a $363.7 million market cap.

AFP by the numbers
More From The Market Online

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…

Little Green Pharma heading into Q2 cashed up after record sales

Little Green Pharma (ASX:LGP) wound up Q1CY24 with $5M in cash after posting record sales of…

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…